IP Verse

Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer Immunotherapy

Patent No. EP3189073 (titled "Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer Immunotherapy") was filed by Cellectis on Sep 3, 2015. The application was issued on Jun 11, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
OXFORD BIOMEDICA UKSep 24, 2020D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3189073

CELLECTIS
Application Number
EP15757289A
Filing Date
Sep 3, 2015
Status
Patent Maintained As Amended
May 9, 2025
Publication Date
Jun 11, 2025
External Links
Slate, Register , Google Patents